H. Burger

发表

Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors

E. Wiemer, N. Naus, R. Mathijssen, 2014, Clinical Cancer Research.

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

S. Bates, J. Verweij, A. Oosterom, 2006, Clinical pharmacology and therapeutics.

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients

E. Wiemer, A. Jager, R. Mathijssen, 2015, Breast Cancer Research and Treatment.

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

J. Verweij, E. de Vries, J. Gietema, 2007, British Journal of Cancer.

Effect of ABCG2 genotype on the oral vioavailability of topotecan

J. Verweij, H. Gelderblom, A. Sparreboom, 2005, Cancer biology & therapy.

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

F. J. Ramos, E. Wiemer, J. Baselga, 2013, Clinical Cancer Research.

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

M. Cotreau, J. Verweij, M. Thomeer, 2011, Clinical Cancer Research.

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.

E. Wiemer, J. Verweij, H. Gelderblom, 2010, European journal of cancer.

Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.

A. W. Boersma, M. Flens, F. Bosman, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

J. Marshall, M. Uttenreuther-Fischer, H. Burger, 2012, Investigational New Drugs.

Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line.

A. W. Boersma, A. Jochemsen, H. Burger, 1995, British Journal of Cancer.

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

S. Sleijfer, J. Blay, F. Collin, 2012, British Journal of Cancer.

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence

E. Wiemer, R. Mathijssen, H. Burger, 2015, Clinical Pharmacokinetics.

Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines.

A. W. Boersma, H. Burger, G. Stoter, 1998, British Journal of Cancer.

Receptor and antibody interactions of human interleukin-3 characterized by mutational analysis.

Colin R. Janssen, M. Mostert, H. Burger, 1991, The Journal of biological chemistry.

Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation

E. Wiemer, R. Mathijssen, H. Burger, 2016, The Prostate.

Lack of correlation between cisplatin‐induced apoptosis, p53 status and expression of Bcl‐2 family proteins in testicular germ cell tumour cell lines

A. W. Boersma, H. Burger, G. Stoter, 1997, International journal of cancer.

Interleukin-3 treatment of rhesus monkeys leads to increased production of histamine-releasing cells that express interleukin-3 receptors at high levels.

H. Burger, G. Wagemaker, Erik Knol, 1995, Blood.

Multidrug resistance-associated protein (MRP) in haematological malignancies.

H. Burger, G. Stoter, K. Nooter, 1996, Leukemia & lymphoma.

Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.

P. Sonneveld, M. Flens, H. Burger, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

High expression of the multidrug resistance‐associated protein (MRP) in chronic and prolymphocytic leukaemia

P. Sonneveld, H. Burger, G. Stoter, 1994, British journal of haematology.

cancer resistance protein (BCRP) / ABCG2 drug pump.

Mariël Brok, H. Burger, G. Stoter, 2013 .

Cancer Therapy : Clinical See related article by Dehm , p . 6064 Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E 7107 in Patients with Advanced Solid Tumors

F. J. Ramos, E. Wiemer, J. Tabernero, 2013 .

Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.

P. Sonneveld, H. Burger, G. Stoter, 1994, Leukemia.

An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors.

J. Verweij, H. Burger, K. Hayashi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distinct p53‐independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines

A. W. Boersma, L. Looijenga, A. Jochemsen, 1999, International journal of cancer.

Acute side effects of homologous interleukin-3 in rhesus monkeys.

H. Burger, G. Wagemaker, C. van den Bos, 1993, The American journal of pathology.

Abstract LB-201: Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors

M. Cotreau, J. Verweij, H. Burger, 2008 .

Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2007, Journal of Cancer Research and Clinical Oncology.

Identification of functional domains of interleukin-3 by construction of primate interspecies chimera.

H. Burger, G. Wagemaker, J. D. de Koning, 1994, Growth factors.

Drug transporters of platinum-based anticancer agents and their clinical significance.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, Drug resistance updates.

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

J. Foekens, J. Klijn, M. Look, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bax upregulation is an early event in cisplatin-induced apoptosis in human testicular germ-cell tumor cell line NT2, as quantitated by flow cytometry.

A. W. Boersma, H. Burger, G. Stoter, 1997, Cytometry.

Characterization of a human multilineage-colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in mouse interleukin-3.

H. Burger, G. Wagemaker, B. Löwenberg, 1987, Gene.

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)

E. Berns, A. W. Boersma, E. Wiemer, 2010, British journal of pharmacology.

Interaction of Imatinib with Human Organic Ion Carriers

S. Baker, R. Franke, A. Sparreboom, 2008, Clinical Cancer Research.

In vitro proliferation of haemopoietic cells in the presence of adherent cell layers. I. Culture conditions and strain dependence.

H. Burger, J. Reimann, 1979, Experimental hematology.

Expression of p53, p21/WAF/CIP, Bcl-2, Bax, Bcl-x, and Bak in radiation-induced apoptosis in testicular germ cell tumor lines.

A. W. Boersma, H. Burger, G. Stoter, 1998, International journal of radiation oncology, biology, physics.

Species specificity of human interleukin-3 demonstrated by cloning and expression of the homologous rhesus monkey (Macaca mulatta) gene

H. Burger, G. Wagemaker, N. Persoon, 1990 .

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

Mariël Brok, E. Wiemer, J. Verweij, 2005, Cancer biology & therapy.

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Mariël Brok, A. W. Boersma, E. Wiemer, 2004, Blood.

Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump

Mariël Brok, A. W. Boersma, E. Wiemer, 2004 .

Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill.

Mariël Brok, A. W. Boersma, H. Burger, 2003, Molecular pharmacology.

SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.

A. W. Boersma, H. Burger, H. den Dulk, 2001, Cancer research.

Loss of SLCO1B3 drives taxane resistance in prostate cancer

E. Wiemer, A. Gibson, A. Sparreboom, 2016, British Journal of Cancer.

Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan.

J. Verweij, H. Gelderblom, A. Sparreboom, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral Neuropathy in Mice Transgenic for a HumanMDR3 P-Glycoprotein Mini-Gene

F. Baas, G. Jansen, P. Borst, 1996, The Journal of Neuroscience.

Production of Human Interleukin-3 Using Industrial Microorganisms

H. Burger, G. Wagemaker, R. Hommes, 1991, Bio/Technology.

Highly Increased Production of Bone Marrow-Derived Blood Cells by Administration of Homologous Interleukin-3 to Rhesus Monkeys

J. Heeney, H. Burger, G. Wagemaker, 1990 .

Highly increased production of bone marrow-derived blood cells by administration of homologous interleukin-3 to rhesus monkeys.

J. Heeney, H. Burger, G. Wagemaker, 1990, Blood.

Species specificity of human interleukin-3 demonstrated by cloning and expression of the homologous rhesus monkey (Macaca mulatta) gene.

H. Burger, G. Wagemaker, R. W. van Leen, 1990, Blood.

Cloning and expression of interleukin-3 genes of chimpanzee and New World monkeys.

M. Mostert, H. Burger, G. Wagemaker, 1994, Biochimica et biophysica acta.

Effects of an inducible anti‐sense c‐myc gene transfer in a drug‐resistant human small‐cell‐lung‐carcinoma cell line

S. de Jong, N. Mulder, H. Burger, 1997, International journal of cancer.

Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype.

Mariël Brok, A. W. Boersma, H. Burger, 2002, Molecular pharmacology.

A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin.

H. Burger, A. Capello, J. Brouwer, 2000, Biochemical and biophysical research communications.

Lysosomal Sequestration Determines Intracellular Imatinib Levels

S. Sleijfer, A. W. Boersma, E. Wiemer, 2015, Molecular Pharmacology.

Lysosomal Sequestration Determines Intracellular Imatinib Levels s

S. Sleijfer, A. W. Boersma, E. Wiemer, 2015 .

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.

J. Verweij, M. D. den Bakker, H. Burger, 2003, European journal of cancer.

Molecular evolution of interleukin-3

J. Leunissen, H. Burger, G. Wagemaker, 1994, Journal of Molecular Evolution.

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

E. Wiemer, J. Verweij, G. Schiavon, 2010, Clinical Cancer Research.

Pharmacokinetic basis for optimal hemopoietic effectiveness of homologous IL-3 administered to rhesus monkeys.

H. Burger, G. Wagemaker, C. van den Bos, 1993, Leukemia.

Neutralizing antibodies during treatment of homologous nonglycosylated IL-3 in rhesus monkeys.

H. Burger, G. Wagemaker, Y. Westerman, 1994, Leukemia.

Interleukin-3 (IL-3) receptors on rhesus monkey bone marrow cells: species specificity of human IL-3, binding characteristics, and lack of competition with GM-CSF.

H. Burger, G. Wagemaker, B. Löwenberg, 1994, Experimental hematology.

Microsoft Word-79110970-file00

E. Wiemer, Sleijfer, M. Debiec‐Rychter, 2015 .

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

J. Verweij, H. Burger, M. D. de Jonge, 2010, British Journal of Cancer.

Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?

E. Wiemer, A. Sparreboom, R. Mathijssen, 2013, Blood.

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.

S. Sleijfer, M. Smid, E. Wiemer, 2017, European journal of cancer.

Drug transporters of platinum-based anticancer agents and their clinical significance.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Advances in Brief SKY 1 Is Involved in Cisplatin-induced Cell Kill in Saccharomyces cerevisiae , and Inactivation of Its Human Homologue , SRPK 1 , Induces Cisplatin Resistance in a Human Ovarian Carcinoma Cell Line 1

A. W. Boersma, H. Burger, J. Brandsma, 2001 .